Company: ABBV
Filing Date: 2025-09-11
Form Type: 8-K
Source: 0001104659-25-089245
Chunk: 0

Company: AbbVie Inc.
Filing Date: 2025-09-11
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure

On September 11, 2025, AbbVie announced that it has settled litigation
with all generic manufacturers that filed abbreviated new drug applications with the U. S. Food and Drug Administration for generic
versions of upadacitinib tablets, which AbbVie markets as RINVOQ.

Given the settlement and license agreements, which are subject to standard
acceleration provisions, assuming pediatric exclusivity is granted, no generic entry for any upadacitinib tablets is expected prior to
April 2037 in the United States.

Some statements in this filing are, or may be considered, forward-looking
statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate,"
"project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie
cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially
from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges
to intellectual property, adverse litigation or government action, changes to laws and regulations applicable to our industry, and other
uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental,
technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024
Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports
on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement
or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking
statements as a result of subsequent events or developments, except as required by law.

The information in this Item 7.01, including the exhibit referenced
herein and attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934 (the “ Exchange Act”), nor shall it be deemed incorporated by reference in any Company filing under the Securities Act
of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits